Evidence map›Paper›PMID 36477547›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

When the Neighboring Village is Not Treated: Role of Geographic Proximity to Communities Not Receiving Mass Antibiotics for Trachoma.

Arman Mosenia, Berhan A Haile, Ayalew Shiferaw, Sintayehu Gebresillasie, Teshome Gebre, Mulat Zerihun, Zerihun Tadesse, Paul M Emerson, E Kelly Callahan, Zhaoxia Zhou and 2 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Arman MoseniaFrancis I. Proctor Foundation, University of California, San Francisco, California, USA.
Berhan A HaileThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Ayalew ShiferawThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Sintayehu GebresillasieThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Teshome GebreThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Mulat ZerihunThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Zerihun TadesseThe Carter Center Ethiopia, Addis Ababa, Ethiopia.
Paul M EmersonThe Carter Center, Atlanta, Georgia, USA.
E Kelly CallahanThe Carter Center, Atlanta, Georgia, USA.
Zhaoxia ZhouFrancis I. Proctor Foundation, University of California, San Francisco, California, USA.
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco, California, USA.
Jeremy D KeenanFrancis I. Proctor Foundation, University of California, San Francisco, California, USA.
The Carter Center · ETCarter Center · USSan Francisco Foundation · USUniversity of California, San Francisco · US

Funding

TANA IIU10EY016214 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIETMAN, THOMAS M · 2004 to 2013
$4.4M
6 · The paper itself

Abstract

backgroundMass administration of azithromycin is an established strategy for decreasing the prevalence of trachoma in endemic areas. However, nearby untreated communities could serve as a reservoir that may increase the chances of chlamydia reinfection in treated communities.

methodsAs part of a cluster-randomized trial in Ethiopia, 60 communities were randomized to receive mass azithromycin distributions and 12 communities were randomized to no treatments until after the first year. Ocular chlamydia was assessed from a random sample of children per community at baseline and month 12. Distances between treated and untreated communities were assessed from global positioning system coordinates collected for the study.

resultsThe pretreatment prevalence of ocular chlamydia among 0 to 9 year olds was 43% (95% confidence interval [CI], 39%-47%), which decreased to 11% (95% CI, 9%-14%) at the 12-month visit. The posttreatment prevalence of chlamydia was significantly higher in communities that were closer to an untreated community after adjusting for baseline prevalence and the number of mass treatments during the year (odds ratio, 1.12 [95% CI, 1.03-1.22] for each 1 km closer to an untreated community).

conclusionsMass azithromycin distributions to wide, contiguous geographic areas may reduce the likelihood of continued ocular chlamydia infection in the setting of mass antibiotic treatments.

Indexed as

Anti-Bacterial AgentsTrachomaAzithromycinChildChlamydia trachomatisHumansInfantMass Drug AdministrationPrevalenceAnti-Bacterial AgentsAzithromycinazithromycingeographic information systemsmass drug administrationocular chlamydiatrachoma

Identifiers

PMID36477547
PMCPMC10226735
OpenAlexW4310945727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.